Abstract
Introduction
Clinically nonfunctioning pituitary adenomas (NFPAs) are relatively common benign tumors of the anterior pituitary gland 1 . These tumors frequently present with symptoms and signs of tumor mass effects on adjacent structures due to the absence of features of pituitary hormone hypersecretion 2 .
The treatment of choice for NFPAs usually is transsphenoidal surgery. The main goals of surgery include complete removal or debulking of the tumor and relieve of tumor mass effects on surrounding structures. Pituitary radiotherapy is an additional treatment option, which may be considered for instance after incomplete surgical resection 3 . After surgery alone, reported rates of tumor recurrence or enlargement range between 6% and 46% 2 . After radiotherapy, recurrence rates of approximately 10% or less have been reported, indicating that adjuvant radiotherapy may improve local tumor control [3] [4] [5] [6] .
The treatment of a NFPA or the effects of the tumor itself often result in the development of hypopituitarism, including growth hormone deficiency (GHD) 2 . The presence of GHD has been reported in up to 85% of NFPA patients 2, 7 .
Adult GHD is, amongst others, associated with adverse changes in cardiovascular risk factors, body composition, bone mineral density, and quality of life 8 . Because growth hormone replacement therapy (GH-RT) has shown beneficial effects on most of these features, many adult GHD patients are nowadays treated with GH-RT 9-11 .
However, some concerns have been raised about the safety of GH-RT in patients with a NFPA, because of the possible stimulating effect of growth hormone (GH) on tumor recurrence or regrowth. Basic research indicates that GH and insulin-like growth factor 1 (IGF-1), through regulation of cell proliferation and apoptosis, may be involved in tumor development and growth 12, 13 . In addition, acromegaly, characterized by elevated GH and IGF-1 concentrations, has been associated with an increased risk of colonic neoplasia 14 . Some epidemiological studies, although not all, suggest that even high-normal IGF-1 concentrations within the age-and gender-adjusted reference range may increase the risk of prostate, colorectal or breast cancer 15 . Studies investigating tumor regrowth or recurrence in pituitary adenoma (PA) patients using GH-RT are relatively scarce in literature 11, [16] [17] [18] [19] [20] [21] [22] [23] . Interpretation and comparison of these studies is difficult due to differences in defining tumor growth, follow-up times and study populations; for example, some studies included patients with various types of PAs.
Despite these limitations, reported data so far seem to be reassuring with regard to effect of GH-RT on tumor regrowth or recurrence, but with the caveat that larger, long-term follow-up studies are needed 21, 24 . To date, essentially three studies have assessed the influence of GH-RT on tumor growth in NFPA patients specifically 17, 19, 20 .
In these studies, tumor regrowth or recurrence did not seem to be affected by GH-RT.
However, study population sizes were relatively small.
The aim of the present study, therefore, was to evaluate tumor regrowth or recurrence in a large cohort of NFPA patients with GH-RT, using data from the Dutch National Registry of Growth Hormone Treatment in Adults, a nationwide long-term surveillance study in severe GHD adult patients.
Subjects and methods

Study population
In 1998, the Dutch National Registry of Growth Hormone Treatment in Adults was initiated by the Dutch Ministry of Health to gain more insight into the long-term efficacy, safety and costs of GH-RT in GHD adults. From that time on, reimbursement of GH-RT costs was only granted after approval of the diagnosis of severe GHD by an independent board of endocrinologists as well as inclusion of anonymized patient data into the registry. All patients were informed by their attending physician. Severe GHD was diagnosed according to the Growth Hormone Research Society consensus guidelines 25 . Data collection, patient characteristics, and test procedures have previously been described in more detail 26, 27 . Until data closure in 2009, 2891 severe GHD adults were registered.
For the present study, all severely GHD patients with a (treated) NFPA (n = 893)
were selected. Patients with < 30 days of GH-RT were excluded (n = 110). Compared to those included in the study (n = 783), excluded patients had a similar age at entry into the registry (p = 0.27), gender (p = 0.69), and onset of GHD (p = 1.00). Patients who were lost to follow-up, who died, or who stopped GH-RT were censored in the analyses. Tumor progression leading to discontinuation of GH-RT was included in the analyses.
Measurements
The data of all registered patients were collected (bi-) annually from medical records by specially trained monitors from the start of enrollment in the registry. When GH-RT had already been started before the first monitor visit, data were retrospectively retrieved. The anonymized collected data were checked for accuracy both before and after entry into the database. In 10% of the patients, data were collected twice by different monitors as an internal quality control.
Persons-years of treatment with GH-RT were calculated from the date of commencement with GH-RT in adulthood (baseline) until the date of last follow-up, discontinuation of GH-RT, or death. The GH dose was titrated on an individual basis by the attending physician with the purpose of achieving and maintaining age-and 
Statistical analysis
Continuous variables were expressed as either mean (SD) or median (range), whereas categorical variables were expressed as number (percentage). The student's t-test was used to compare normally distributed continuous variables, whereas the MannWhitney test was used for skewed variables. Categorical variables were compared with the Chi-square or Fisher's exact test.
Kaplan-Meier survival curves were used to describe the progression-free survival.
Cox proportional hazard analysis was used to evaluate the risk of developing tumor progression in patients who had received prior radiotherapy compared with those who had not received prior radiotherapy and in patients with residual tumor at baseline compared with patients without residual tumor at baseline, respectively. In all analyses, time was measured from start of GH-RT in adulthood until the date of first tumor progression, last follow-up, or death, whichever occurred first. Assumptions of proportional hazards were tested by log-minus-log plots and interaction terms. To adjust for the potentially confounding effects of age at baseline and gender, these variables were included in the Cox proportional hazard models. Other potentially confounding variables, including age at NFPA diagnosis, extension of pituitary deficiency (isolated GHD or multiple pituitary hormone deficiencies), pituitary surgery, radiotherapy and history of tumor progression were examined by adding them separately to the age-and gender-adjusted models. Variables that gave a change in the regression coefficient of > 10% were included in the model. All continuous variables were individually checked for linearity with the outcome variable and, in case of nonlinearity, divided in categories. Potential effect modification by gender was examined by adding an interaction term to the age-and gender-adjusted model. In case of a p-value < 0.10, analyses were stratified for gender.
All statistical analyses were performed using the statistical software package IBM
SPSS Statistics version 20 (SPSS Inc)
. Two-sided p-values of ≤ 0.05 were considered significant.
Results
Baseline characteristics
Severe GHD was diagnosed with a GH stimulation test in 702 (89.7%) of the 783 patients included in the study (54.8% insulin tolerance test, 23.4% GH-releasing hormone
[GHRH]/arginine test, 13.4% arginine test, 8.0% GHRH test, 0.4% other). In 75 (9.6%) patients, the diagnosis was based on IGF-1 concentrations ≤ 2 SD in combination with two or more additional pituitary hormone deficiencies. In the remaining cases, either retesting was considered unnecessary because of childhood onset GHD due to evident hypothalamic pituitary disease (n = 2 [0.3%]) or the diagnostic procedure was
Characteristics of the total study population and of patients with and without tumor progression during follow-up are shown in table 1. In operated patients, the surgical approach was transsphenoidal in 580 (79.9%) of the cases, transcranial in 118 (16.3%), and unknown in 28 (3.8%). Most irradiated patients (66.7%) were treated with conventional radiotherapy, whereas a minority (5.9%) received stereotactic radiotherapy. In the remaining cases (30%), the method used was unknown.
In 596 (76.1%) patients, baseline pituitary imaging data were available (table 2) .
Compared to those with baseline imaging data, patients without baseline imaging data had a similar age at baseline (p = 0.22), gender (p = 0.84), occurrence of tumor progression (p = 0.14) and duration of GH-RT (p = 0.10). 
Growth hormone replacement therapy
The median follow-up time for the total study population was 5. 
Progression-free survival and comparison of subgroups
The progression-free survival of the total study population is shown in figure 1 . Of all patients, 399 (51.4%) had received radiotherapy as part of the prior tumor treatment (in six patients it was unknown whether they had received radiotherapy). Tumor In 363 (62.6%) of the patients with baseline imaging data, there was evidence of residual adenoma at baseline (table 2) . Tumor progression was observed in 65 (17.9%) of these patients, whereas in patients without residual tumor this was observed in Within the group of patients without residual tumor at baseline, two (2.1%) patients with prior radiotherapy developed tumor progression vs. 11 (9.3%) patients without prior radiotherapy.
Discussion
GHD frequently occurs in patients with NFPAs, either as a consequence of the treatment of the tumor, the tumor itself, or a combined effect of both 2,7 . GH-RT has shown positive effects on features associated with adult GHD 9-11 . However, it has been suggested GH-RT may increase the risk of tumor recurrence or growth, despite mostly reassuring data in literature so far 24 . In the present observational study in a large cohort of NFPA patients using GH-RT, tumor progression developed in 12.1%
of the patients after a median of 2.2 (0.1 -14.9) years after starting GH-RT in adulthood.
Radiotherapy as part of prior NFPA treatment significantly decreased the risk of tumor progression. Residual tumor was associated with an increased risk of tumor progression.
Several studies have investigated recurrence or regrowth of PAs after surgery and/or radiotherapy in patients not using GH-RT. In a series of 159 NFPA patients, tumor recurrence or regrowth occurred in 33.5% after a median of 4.1 (1 -20.7) years following surgery 28 . In two other studies including NFPA patients who had undergone transsphenoidal surgery, recurrence rates were 21% and 32%, respectively 29, 30 . After pituitary radiotherapy, lower recurrences rates have been reported 5 . Gittoes et al.
found that only 4 of 63 (6%) postoperatively irradiated NFPA patients developed tumor progression, whereas 27 of 63 (43%) patients who were not postoperatively irradiated developed tumor progression 3 . Likewise, in a cohort of 122 NFPA patients, tumor progression occurred in 4% and 57%, respectively, of patients with and without postoperative radiotherapy 4 . In a series of 411 patients with various types of PAs who had all received radiotherapy, whether or not combined with surgery, only 25 (6%) patients developed tumor progression 6 . The tumor progression rates in the entire cohort and in patients with or without prior radiotherapy of 12.1%, 4.8% and 20.1%, respectively, in the present study, appear to be similar to or lower than those reported by the abovementioned studies. This could indicate that GH-RT may not impose an increased risk of tumor progression in NFPA patients. However, several aspects that may widely vary between studies, such as treatment related factors (e.g. surgical technique, extent of surgery, radiotherapy), study population, tumor characteristics, and follow-up duration have to be taken into account when comparing different studies.
So far only few studies in the literature have explored the possible effect of GH-RT on tumor progression in NFPA patients specifically 11, 17, 19, 20 . Buchfelder et al. revealed that GH-RT was not a significant predictor of progression after adjustment for several confounders. In another case-control study in NFPA patients using GH-RT (n = 121) or not (n = 114), the progression-free survival rates were similar in both groups 17 . During an observation period of approximately 10 years, tumor progression was found in 26% of the GH-treated patients and in 32% of the non-GH-treated patients. Although the nonrandomized nature of these studies could have led to bias with regard to the choice for GH-RT, for instance, because patients with larger (residual) tumors may have been less likely to receive GH-RT and the sample sizes were limited, all these studies suggest that GH-RT does not increase tumor progression risk.
The observed tumor progression rates in the present study seem to be comparable with or lower than those reported in literature. The rate of 12.1% in our entire study population was lower than those in the treatment and control groups of the three aforementioned studies 17, 19, 20 . This may be due to differences in sample size, whether radiotherapy was administered, or follow-up time. Nevertheless, the results of the present study support data in literature that GH-RT, aiming at restoring physiological IGF-1 concentrations, does not appear to have a negative impact on tumor progression in patients with a NFPA. 18, 38 . These findings are line with previous reports from our registry. In one study, mortality due to malignancies was not elevated in adults receiving GH-RT compared to the background population 27 . In another study, the occurrence of secondary intracranial tumors did not differ between irradiated and nonirradiated NFPA patients (1.1% vs. 0.6%), but the risk of CVE was increased in irradiated men 31 .
Overall, as discussed in a recent review, fatal and nonfatal malignancies do not appear to be more prevalent in GH-treated adults compared to the general population, and also not in previously irradiated patients 11, 18 . Nevertheless, potential side effects of pituitary irradiation should be carefully balanced against benefits.
The presence of residual tumor at baseline significantly increased tumor progression risk in the present study, also after adjustment for potential confounders. This has also been observed by others 17, 20, 21 . Olsson et al. found that tumor progression developed in 37% and 10% of patients using GH-RT with and without residual tumor, respectively, compared to 17.9% and 6.1% in the present study 17 . They suggested that, because the rates in their treatment group, including patients with residual tumor, were comparable with those in the control group and those in literature, GH-RT may also be safely administered in patients with residual tumor. This is in line with the findings in the present study. For instance, in the subgroup of our patients with residual tumor who had not received radiotherapy, 28.9% developed tumor progression, which is comparable with reported ranges, varying between 21% and 57%, in surgically treated, but nonirradiated, NFPA patients not using GH-RT 3, 4, 19, [28] [29] [30] . In addition,
Arnold et al. showed that after adjustment for several confounders, including type of tumor removal (partial or complete), GH-RT was not a predictor of recurrence 19 . These combined data indicate that GH-RT may also be initiated in the presence of residual NFPA, although long-term surveillance is recommended.
The present study has both strengths and limitations. The large size of the study population, including only patients with a NFPA and excluding other types of tumors, is one of the major strengths. Due to this large number, comparisons between different subgroups could be made. Furthermore, potentially confounding effects of several factors were evaluated. The follow-up duration was relatively long and similar between patients with and without tumor progression. However, one could argue that the follow-up period might not have been long enough to detect tumor growth in the usually slow-growing NFPAs. A limitation of our study is the lack of a control group of untreated GHD patients with a NFPA. However, our findings were compared with those in literature, thereby taking into account the difficulties of such comparisons.
The nonrandomized and retrospective design, inherent to the observational nature of the database, presents another limitation. Unfortunately, performing a prospective randomized study in NFPA patients does not seem feasible due to practical and ethical constraints.
In summary, in this observational study in a large number of NFPA patients using GH-RT, the development of tumor progression was investigated. The findings in this study in combination with those reported in literature, thereby taking into account the presented limitations, indicate that GH-RT does not seem to increase the risk of tumor progression. Although more robust conclusions may only be generated by large randomized prospective studies with long-term follow-up, evidence so far seems reassuring. Data suggest that GH-RT, with regard to tumor progression, may be safely administered to GHD patients with a NFPA.
